MMSM,MultipleMyeloma,ODAC

Mashup Score: 2

FDA’s ODAC Votes in Favor of Risk/Benefit Profile of Subcutaneous Daratumumab for High-Risk Smoldering Myeloma - 3 day(s) ago

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Source: www.onclive.com

Categories: General Medicine News

Tweet Tweets with this article
- OncLive
  
  BREAKING🚨: @US_FDA's ODAC Votes in Favor of Risk/Benefit Profile of Subcutaneous Daratumumab for High-Risk Smoldering Myeloma #MMSM #MultipleMyeloma #ODAC https://t.co/GniWdim3Rp https://t.co/HfAj3lUtcq